Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TC-5619 for negative symptoms and cognition in schizophrenia
NCT01488929Phase 2Completed
- Sponsor
- Targacept
- Start
- Dec 2011
- Primary completion
- Nov 2013
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of bradanicline in schizophrenia, sponsored by Targacept. Started Dec 2011; status: completed.
02
Drugs
bradanicline
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01488929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01488929.